RESEARCH PAPER
Nebulization therapy in children with cystic fibrosis – opinions of the children and their parents
 
More details
Hide details
1
Katedra i Zakład Pielęgniarstwa Pediatrycznego, Wydział Pielęgniarstwa i Nauk o Zdrowiu, Uniwersytet Medyczny w Lublinie
 
Med Og Nauk Zdr. 2012;18(4):287–290
 
KEYWORDS
ABSTRACT
Introduction:
Nebulization is considered a very good and effective method for inhaled drug delivery. Despite some disadvantages, its effectiveness, accessibility and ease of use has resulted in it attaining an established position among the treatments for respiratory diseases; therefore, the possibility of its application should always be considered.

Objective:
To obtain the opinions of children with cystic fibrosis and their parents about nebulization therapy, which affect the effectiveness of treatment.

Material and Methods:
A survey was conducted in 2008 among 100 children with cystic fibrosis using nebulization therapy, and among 100 of their parents. The study included 51 children hospitalized in the Institute of Tuberculosis and Lung Diseases in Rabka, 2 children hospitalized in the Department of Pulmonary Diseases and Rheumatology of the University Children’s Hospital in Lublin, and the 47 children who are members of the Polish Society of cystic fibrosis patients, with headquarters in Rabka.

Results:
Analysis of the research material shows that the majority of children surveyed (79%), and in the opinions of their parents (85%), the children willingly performed nebulization. Also, most children (86%) and parents (92%) knew the benefits of nebulization therapy. Nearly all the sick children (82%) and their parents (94%) accepted nebulization therapy. The great majority of children (89%) and parents (94%) agreed that nebulization therapy gives good results. A large percentage of the children (91%) and parents (83%) stated that nebulizer equipment is readily available to them. However, 13% of the children and 11% of their parents were not satisfied with the applied nebulization therapy. As many as 83% of the children and 73% of their parents felt that the nebulizer equipment was unwieldy. A large percentage of children (68%) and slightly less of their parents (22%) did not accept the noise related to operation of a nebulizer. As many as three-quarters (79%) of children and their parents (73%) stated that the costs related with nebulization therapy significantly influenced the worsening of financial situation of the family. Unfortunately, 61% of the children and 47% of their parents claimed that nebulization therapy impedes normal functioning of the child. Among the drawbacks of this therapy, the respondents listed long duration of treatment, the need for access to a power supply, and the need to clean the nebulizer.

Conclusions:
1. Despite the indication of some of its drawbacks, the opinions of children with cystic fibrosis and their parents about nebulization therapy were mostly positive. 2. To achieve optimal results of treatment, there is a need for continuing education among them about the rules of nebulization therapy, possible use of modern nebulizers and obtain funding for their use.

 
REFERENCES (19)
1.
Bush A, Alton E, Davies J, Griesenbach U, Jaffe A. Cystic Fibrosis in the 21st Century. Basel: Karger; 2006.
 
2.
Borowitz D, Baker R, Stallings V. Consensus Report in Nutrition for Pediatric Patients with Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35: 246.
 
3.
Boucher RC. New concept of pathogenesis of cystic fibrosis lung disease. Eur Resir J. 2004; 23: 146.
 
4.
Pogorzelski A. Mukowiscydoza – choroba nie tylko układu oddechowego. Klin Ped. 2002; 10(2): 263-266.
 
5.
Emeryk A, Bręborowicz A, Lis G. (red.) Astma i choroby obturacyjne oskrzeli u dzieci. Wrocław: Elsevier Urban&Partner; 2010.
 
6.
Collins FS. Cystic fibrosis: molecular biology and therapeutic implica¬tions. Since 1992; 256: 774.
 
7.
Walkowiak J, Cichy W. Mukowiscydoza – nadal aktualny problem diagnostyczny I terapeutyczny. Przew Lek. 2001; 9: 86.
 
8.
Dębska G. Jakość życia chorych na muskowidozę. Acta Pneumonol Allergol Pediatr. 2003; 3(6): 39-40.
 
9.
Zasady rozpoznawania i leczenia mukowiscydozy. Stanowisko Polskiej Grupy Roboczej Mukowiscydozy. Stand Med. 2005; 2(5): 16-27.
 
10.
Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med. 1996; 90: 69-77.
 
11.
Cichosz-Jarosz E. Technika i zasady stosowania leków. W: Nebulizacja w leczeniu chorób dolnych dróg oddechowych u dzieci. Med Prakt. 2001; 05: 25-26.
 
12.
Alkiewicz J. Nebulizatory – wady i zalety stosowania. Przew Lek. 2000; 5: 12.
 
13.
Emeryk A, Kurzawa R, Bręborowicz A. (red.) Aerozoloterapia chorób układu oddechowego u dzieci. Wrocław: Urban&Partner; 2007.
 
14.
Alkiewicz J. (red.) Leczenie inhalacyjne i rehabilitacja układu oddechowego u dzieci i dorosłych. Wrocław: Volumed; 1995.
 
15.
Alkiewicz J. Aerozoloterapia w chorobach układu oddechowego u dzieci. Przew Lek. 2001; 6: 55.
 
16.
Milanowski A. (red.) Choroby układu oddechowego. Warszawa: PZWL; 2000.
 
17.
Alkiewicz J. Aerozoloterapia w chorobach układu oddechowego u dzieci. W: Pawlaczyk B. (red.) Zarys pediatrii. Warszawa: PZWL; 2005: 238-244.
 
18.
Mazurek H. Mukowiscydoza. W: Emeryk A., Bręborowicz A, Lis G. Astma i choroby obturacyjne oskrzeli u dzieci. Wrocław: Elsevier Urban&Partner; 2010: 301-308.
 
19.
Lis G. Techniki inhalacyjne. W: Emeryk A, Bręborowicz A, Lis G. Astma i choroby obturacyjne oskrzeli u dzieci. Wrocław: Elsevier Urban&Partner; 2010: 325-330.
 
eISSN:2084-4905
ISSN:2083-4543